FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis
PMA: P180047
·
Supplement: S019
·
Decision Jul 18, 2023
Classifications
1
FEI Numbers
4
Registration Numbers
4
Basic Information
- Device Name
- Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis
- Trade Name
- LIAISON QuantiFERON-TB Gold Plus
- PMA Number
- P180047
- Supplement Number
- S019
- Device Class
- FDA Class 3
- Product Code
- NCD
- Generic Name
- TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- July 18, 2023
- Date Received
- August 1, 2022
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for a change in the conjugate reagent in the LIAISON QuantiFERON TB Gold Plus assay from a lyophilized format to a liquid format.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| NCD | Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis | FDA class 3 | Unknown |